The role of extracellular vesicles and interleukin-8 in regulating and mediating neutrophil-dependent cancer drug resistance

Tumor drug resistance is a multifactorial and heterogenous condition that poses a serious burden in clinical oncology. Given the increasing incidence of resistant tumors, further understanding of the mechanisms that make tumor cells able to escape anticancer drug effects is pivotal for developing ne...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 947183
Main Authors Zippoli, Mara, Ruocco, Anna, Novelli, Rubina, Rocchio, Francesca, Miscione, Martina Sara, Allegretti, Marcello, Cesta, Maria Candida, Amendola, Pier Giorgio
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 16.12.2022
Subjects
drug resistance
extracellular vesicles
interleukin-8
NETosis
neutrophil
Oncology
Tumor-associated neutrophils
Tumor-associated neutrophils
NETosis
extracellular vesicles
drug resistance
interleukin-8
neutrophil
Online AccessGet full text

Cover

More Information
Summary:Tumor drug resistance is a multifactorial and heterogenous condition that poses a serious burden in clinical oncology. Given the increasing incidence of resistant tumors, further understanding of the mechanisms that make tumor cells able to escape anticancer drug effects is pivotal for developing new effective treatments. Neutrophils constitute a considerable proportion of tumor infiltrated immune cells, and studies have linked elevated neutrophil counts with poor prognosis. Tumor-associated neutrophils (TANs) can acquire in fact immunoregulatory capabilities, thus regulating tumor progression and resistance, or response to therapy. In this review, we will describe TANs' actions in the tumor microenvironment, with emphasis on the analysis of the role of interleukin-8 (IL-8) and extracellular vesicles (EVs) as crucial modulators and mediators of TANs biology and function in tumors. We will then discuss the main mechanisms through which TANs can induce drug resistance, finally reporting emerging therapeutic approaches that target these mechanisms and can thus be potentially used to reduce or overcome neutrophil-mediated tumor drug resistance.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Gabi U. Dachs, University of Otago, New Zealand
Reviewed by: Simona Bernardi, University of Brescia, Italy; Monisha Samuel, National Forensic Sciences University, India
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
These authors have contributed equally to this work and share first authorship
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.947183